Lack of efficacy of macrocyclic lactones, albendazole, and levamisole against a field population of Dictyocaulus viviparus in cattle

IF 1.4 Q3 PARASITOLOGY

Veterinary parasitology, regional studies and reports Pub Date : 2025-08-14 DOI:10.1016/j.vprsr.2025.101329

Mateus Lotério Coelho , Dyego Gonçalves Lino Borges , Ivanise Paula Sobota , Ricardo Antônio Amaral de Lemos , Danilo Carloto Gomes , Fernando de Almeida Borges

{"title":"Lack of efficacy of macrocyclic lactones, albendazole, and levamisole against a field population of Dictyocaulus viviparus in cattle","authors":"Mateus Lotério Coelho , Dyego Gonçalves Lino Borges , Ivanise Paula Sobota , Ricardo Antônio Amaral de Lemos , Danilo Carloto Gomes , Fernando de Almeida Borges","doi":"10.1016/j.vprsr.2025.101329","DOIUrl":null,"url":null,"abstract":"<div><div>Dictyocaulus viviparus (Strongylida: Dictyocaulidae) is the etiological agent of pulmonary parasitosis in cattle, causing severe respiratory symptoms and, in extreme cases, death. Outbreaks of D. viviparus were recorded on a property in Brazil in the years 2022 and 2023 in an integrated agriculture and livestock system. Treatment failure was observed for levamisole, macrocyclic lactones and benzimidazoles, and only the combination of levamisole (18.8 %) and moxidectin (1 %) was effective according to fecal larvae counting reduction test (FLCRT). The following efficacy rates were observed: albendazole sulfoxide (15 %), 60.10 %; moxidectin (1 %), 60.30 %; ivermectin (0.8 %) + albendazole sulfoxide (10 %), 43.30 %; ivermectin (3.15 %), 9.85; levamisole (18.8 %), 27.40 %; doramectin (3.5 %), 57.30 % in 2022; moxidectin (1 %), 89.20 %; doramectin (1 %), 31.70 %; ivermectin (0.8 %) + albendazole sulfoxide (10 %), 19.10 %; doramectin (1.1 %), 2.22 %; levamisole (18.8 %), 96.30 %; doramectin (3.5 %), 88.40 %; and levamisole (18.8 %) + moxidectin (1 %), 99.70 % in 2023. The present results underscore the importance of monitoring pulmonary parasitosis and the scenario of lack of efficacy found in the studied population of D. viviparus.</div></div>","PeriodicalId":23600,"journal":{"name":"Veterinary parasitology, regional studies and reports","volume":"64 ","pages":"Article 101329"},"PeriodicalIF":1.4000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary parasitology, regional studies and reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405939025001376","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PARASITOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Dictyocaulus viviparus (Strongylida: Dictyocaulidae) is the etiological agent of pulmonary parasitosis in cattle, causing severe respiratory symptoms and, in extreme cases, death. Outbreaks of D. viviparus were recorded on a property in Brazil in the years 2022 and 2023 in an integrated agriculture and livestock system. Treatment failure was observed for levamisole, macrocyclic lactones and benzimidazoles, and only the combination of levamisole (18.8 %) and moxidectin (1 %) was effective according to fecal larvae counting reduction test (FLCRT). The following efficacy rates were observed: albendazole sulfoxide (15 %), 60.10 %; moxidectin (1 %), 60.30 %; ivermectin (0.8 %) + albendazole sulfoxide (10 %), 43.30 %; ivermectin (3.15 %), 9.85; levamisole (18.8 %), 27.40 %; doramectin (3.5 %), 57.30 % in 2022; moxidectin (1 %), 89.20 %; doramectin (1 %), 31.70 %; ivermectin (0.8 %) + albendazole sulfoxide (10 %), 19.10 %; doramectin (1.1 %), 2.22 %; levamisole (18.8 %), 96.30 %; doramectin (3.5 %), 88.40 %; and levamisole (18.8 %) + moxidectin (1 %), 99.70 % in 2023. The present results underscore the importance of monitoring pulmonary parasitosis and the scenario of lack of efficacy found in the studied population of D. viviparus.

Abstract Image

查看原文本刊更多论文

大环内酯、阿苯达唑和左旋咪唑对牛活体双头绦虫缺乏防治效果

胎生圆虫（圆线虫：圆虫科）是牛肺寄生虫病的病原，可引起严重的呼吸道症状，在极端情况下可导致死亡。在巴西的一个农业和畜牧综合系统中，记录了2022年和2023年的胎生疟暴发。左旋咪唑、大环内酯和苯并咪唑治疗无效，仅左旋咪唑（18.8%）和莫西丁素（1%）联合治疗有效。观察有效率：阿苯达唑亚砜（15%）、60.10%；莫西丁（1%），60.30%；伊维菌素(0.8%)+阿苯达唑亚砜（10%），43.30%；伊维菌素（3.15%），9.85；左旋咪唑（18.8%）、27.40%；Doramectin(3.5%)， 2022年57.30%；莫西丁（1%），89.20%；多拉菌素（1%），31.70%；伊维菌素(0.8%)+阿苯达唑亚砜（10%），19.10%；多拉菌素（1.1%），2.22%；左旋咪唑（18.8%），96.30%；多拉菌素（3.5%），88.40%；左旋咪唑(18.8%)+莫西丁（1%），2023年为99.70%。目前的结果强调了监测肺寄生虫病的重要性和在研究种群中发现的缺乏疗效的情况。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Veterinary parasitology, regional studies and reports Multiple-

CiteScore

2.90

自引率

7.10%

发文量

126

审稿时长

97 days

期刊介绍： Veterinary Parasitology: Regional Studies and Reports focuses on aspects of veterinary parasitology that are of regional concern, which is especially important in this era of climate change and the rapid and often unconstrained travel of people and animals. Relative to regions, this journal will accept papers of the highest quality dealing with all aspects of disease prevention, pathology, treatment, epidemiology, and control of parasites within the field of veterinary medicine. Also, case reports will be considered as they add to information related to local disease and its control; such papers must be concise and represent appropriate medical intervention. Papers on veterinary parasitology from wildlife species are acceptable, but only if they relate to the practice of veterinary medicine. Studies on vector-borne bacterial and viral agents are suitable, but only if the paper deals with vector transmission of these organisms to domesticated animals. Studies dealing with parasite control by means of natural products, both in vivo and in vitro, are more suited for one of the many journals that now specialize in papers of this type. However, due to the regional nature of much of this research, submissions may be considered based upon a case being made by the author(s) to the Editor. Circumstances relating to animal experimentation must meet the International Guiding Principles for Biomedical Research Involving Animals as issued by the Council for International Organizations of Medical Sciences (obtainable from: Executive Secretary C.I.O.M.S., c/o W.H.O., Via Appia, CH-1211 Geneva 27, Switzerland).